Author(s):
Year:
Parent‐metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients with BRCA 1/2–mutated Cancer or PARP‐sensitive Tumor Types
Recommended for you
- Solutions
- Solutions
Transform your drug development journey with Certara’s comprehensive solutions. From molecule to market, we seamlessly integrate science, technology, strategic and regulatory expertise to solve your unique challenges.
Discover more
Strategic LeadershipUnify insights to accelerate drug development and achieve development milestones. Partner with Certara to unlock your pipeline’s potential.
Learn more
- Software
- Our software
Certara’s software solutions offer transformative approaches across all drug development phases, aligning with recognized industry standards. By integrating advanced modeling, analytics, and automation, they break down silos, streamline workflows, and drive regulatory success.
View all
- Featured software:
- Software by solutionRegulatory Discovery Preclinical Early Clinical Late Clinical Market Access & Commercial View software
- Services
- Our services
Transform drug development with our tailored services. From predictive modeling to market access strategies, Certara’s integrated services enhance decision-making, streamline processes, and make your drug a safer bet.
View all
- Services by solutionRegulatory Discovery Preclinical Early Clinical Late Clinical Market Access & Commercial View services
- Customers
- Customers
Certara tailors solutions for biotech, pharma, and CROs, addressing unique challenges to drive success.
Learn who we work with
-
Transforming Partnerships
Certara collaborates with leading biotech, pharma, and CRO partners to tackle complex challenges, deliver innovation, and shape the future of healthcare.
Learn more
- Resources
- Resources
With over 1,000 articles spanning categories and solutions, Certara’s resources is a geek haven. It’s all here—built for scientists who dare to think different.
View all
- Featured resources:
- Resources by solutionRegulatory Discovery Preclinical Early Clinical Late Clinical Market Access & Commercial View all resources
- Company
- Explore Certara
With over 1,550+ employees in more than 30 countries, over 28% of which have PhDs, our vision is to transform drug development for good.
Learn more about us
-
Careers at Certara
Join a global leader transforming the future of drug development. Explore opportunities to innovate, grow, and make a difference in transforming lives.
Visit careers site
search
Home / Publication / Parent‐metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients with BRCA 1/2–mutated Cancer or PARP‐sensitive Tumor Types
Parent‐metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients with BRCA 1/2–mutated Cancer or PARP‐sensitive Tumor Types
Newsletter sign up
Why sign up? Because transforming drug development is not just our goal—it’s our obsession. If it’s yours too, then be the first to know of new insights and join us in pushing the boundaries of science.
Solutions
© 2025 Certara. All Rights Reserved. | Privacy policy